Combination of Veliparib and Chemotherapy in BRCA-Positive Breast Cancer

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

Jordyn Sava;Aditya Bardia, MD, MPH

February 6th 2025

Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Russ Conroy

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.

Jordyn Sava;Sanjay K. Juneja, MD

January 15th 2025

First-Line Adagrasib Shows Activity in STK11-Mutant KRAS G12C NSCLC

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

New Standard of Care? KEYNOTE-689 Results in LA-HNSCC

Adagrasib shows initial promise, tolerability, and encouraging response rates in STK11/KRAS G12C-mutant lung cancer.

FDA Clears LP-184 IND for TNBC Trial as Monotherapy & PARP Inhibitor Combo

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Related Content

Sabrina Serani

May 6th 2025

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

Jordyn Sava;Aditya Bardia, MD, MPH

February 6th 2025

Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Russ Conroy

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD

January 15th 2025

First-Line Adagrasib Shows Activity in STK11-Mutant KRAS G12C NSCLC

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

New Standard of Care? KEYNOTE-689 Results in LA-HNSCC

Adagrasib shows initial promise, tolerability, and encouraging response rates in STK11/KRAS G12C-mutant lung cancer.